PolyPid climbs after data safety panel recommendation on late-stage trial

Polypid

23/05/2022 16:30

** U.S.-listed shares of Israel-based drug developer
 PYPD.O  rise nearly 9% to $5.35
    ** PYPD says an independent data safety monitoring panel
recommended that a late-stage study of PYPD's drug candidate,
D-PLEX100, be concluded upon enrollment of 950 patients - the
minimum number targeted in the trial plan  urn:newsml:reuters.com:*:nGNX4yYD5y
    ** Recommendation followed the panel's review of data from
the first 750 patients enrolled in the study, testing the drug
for the prevention of surgical site infections (SSIs) in
abdominal tissue surgery
    ** Enrollment of the 950th patient is expected to occur
within days; top line results expected by end of Q3 - company
    ** Aims to submit marketing applications to the U.S. and
European drugs regulator in H1 2023
    ** Stock down 6.8% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))